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ABSTRACT 
Background: Vocal Cord Dysfunction (VCD) typically involves abnormal adduction of the vocal 
cords during inspiration, mimics the symptoms of asthma and leads to the prescription of ineffective 
medications.  
Objective: We aimed to develop a clinical tool to monitor symptoms and response to treatment in 
confirmed VCD. 
Methods: We collated symptoms of VCD from focus groups comprising patients and healthcare-
professionals; phrases describing these symptoms were assessed for face validity and internal 
correlation, and rated for importance.  The resultant 12 item questionnaire (VCDQ) rated the impact 
of each on a 5-point Likert scale (total score range 12 to 60), and was tested for reliability, concurrent 
validity and performance in 31 patients with endoscopically confirmed VCD (± asthma), 29 
asthmatics with no history of VCD, and 14 healthy controls.  We assessed response to speech and 
language therapy and the minimal important difference by measuring the VCDQ pre- and post- 
therapy in a 20 new patients.  
Results: The VCDQ had excellent test-retest reliability, and differentiated VCD versus healthy 
(Mann-Whitney test: z = -5.390, P < 0.001) and asthma (z = -5.730, p < 0.001). All patients improved 
post-therapy, assessed both by a global rating of change score (GRCS) and by the VCDQ [median 
(IQR) score pre-therapy 50.5 (48.0 – 54.8), post therapy 35.0 (29.3 – 41.8), p < 0.001].  The minimal 
important difference in the VCDQ associated with a rating of “minimally better” on the GRCS was 4 
points.  
Conclusions and Clinical Relevance: The VCDQ is a valid and responsive tool suitable for 
measuring changes in symptoms in patients with VCD.  It also gives insight into which symptoms are 
important to patients, and could guide future therapy refinements. Future assessments of novel 
therapies for this condition should use an appropriately validated tool such as the VCDQ to measure 
response. 
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INTRODUCTION 
Vocal cord dysfunction (VCD) manifests as abnormal adduction of the vocal cords during breathing, 
resulting in episodes of extrathoracic airway obstruction and breathlessness [1].  Presenting symptoms 
closely resemble those of asthma, with intermittent wheeze and dyspnoea often following exposure to 
triggers such as exercise [2] or pollutants [3].  Therefore the majority of sufferers receive an initial 
diagnosis of asthma [4].  However, VCD will not respond to asthma medication, although often 
therapy is stepped up progressively resulting in treatment with high dose inhaled and oral steroids 
without benefit, but significant risk of adverse effects [5].  There is also frequent use of emergency 
services among VCD sufferers with one retrospective study [4] reporting ten presentations to the 
emergency department and six hospital admissions per patient per year, and another that VCD patients 
had significantly more hospital visits than a comparator group with moderate persistent asthma [6].  
The same study also reported that on average asthma had been misdiagnosed for five years before a 
correct diagnosis of VCD was made.  Severe acute presentations of VCD can even result in tracheal 
intubation or tracheotomy [7].  Despite this, the term VCD is only mentioned once in the British 
Thoracic Society asthma guidelines [8] and only four times in the joint European Respiratory Society 
/ American Thoracic Society asthma guidelines [9]. 
 
Vocal cord dysfunction can present at any age and appears to be more common in females [10].  It has 
been thought to be a relatively rare condition and does not feature prominently in medical teaching 
programmes.  It is likely therefore that in general the clinical index of suspicion is low.  One study 
reviewed 120 cases of exertional dyspnoea and found that VCD was the cause in 12% [11], 
suggesting it may be more prevalent than generally appreciated.  The pathophysiology of VCD is 
poorly understood and sometimes considered to be mainly a psychological disorder with labels used 
such as "Munchausen's Stridor" and "factitious asthma" [12].  Whilst psychological factors 
undoubtedly sometimes play a role in the presentation of VCD, there is now greater recognition of 
other contributing factors, such as laryngopharyngeal reflux and underlying lung and nasal disease 
[13,14].    
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The gold standard for diagnosis of VCD requires direct visualisation of paradoxical vocal cord 
movement on laryngoscopy whilst the patient is symptomatic [15].  This requires specialist skills and 
knowledge that is not currently widely available.  A high index of suspicion is required to identify 
patients with the condition who require further investigation.  There has been no systematic 
investigation to date of the symptoms reported by patients with VCD, and how these might differ 
from asthma.  Management of VCD involves a multi-disciplinary approach and should include 
treating any identifiable cause (e.g. gastro-oesophageal reflux disease), avoiding triggers, specific 
psychological counselling, and speech and language therapy.  The latter involves techniques to focus 
on expiration and diaphragmatic breathing, and is considered the main treatment for chronic VCD 
[16].  We have performed a qualitative study investigating symptoms in VCD with the aim of 
monitoring response to these treatment interventions. 
 
METHODS 
Adult patients with endoscopically proven VCD were recruited from our specialist airways clinic.  
The group contained patients both with VCD as the sole diagnosis and others with both VCD and a 
clinical diagnosis of asthma.  All patients were awaiting or currently undergoing treatment with 
speech and language therapy.  Patients with a physician’s diagnosis of asthma but without VCD were 
recruited from the same clinic.  Healthy controls, with no history of respiratory disease, were recruited 
from the community.  All participants gave their written informed consent before inclusion and 
approval for this study was obtained from the North West 12 Regional Ethics Committee (Lancaster).   
 
The VCD questionnaire (VCDQ) was developed using a three-stage approach as employed by 
previous respiratory symptom questionnaires [17].  Stage I - item generation, Stage II - item reduction 
(A - face validity, B - importance, C - correlation), and Stage III - validation (A - test-retest reliability, 
B - concurrent validity, C - performance).   The intention was to produce a questionnaire comprising a 
broad range of symptoms that could be used to monitor longitudinal changes in the condition. 
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Stage I: Item Generation 
An initial literature search was carried out which revealed no previous publications relating to VCD 
specific symptom questionnaires, and information from the VCD literature was used to aid item 
generation.  Two sets of focus groups were held, one including nine healthcare professionals (a mix of 
specialist and general respiratory physicians and allied healthcare professionals) and the other fifteen 
patients with proven VCD, in order to generate a long list of statements relating to symptoms and 
quality of life issues. 
 
Stage II: Item Reduction 
Stage IIA (Face Validity):  The list of statements was given to ten participants with a diagnosis of 
VCD initially to ask if each item made sense.  Items were removed if their meaning was not clear to 
two or more of the group.  
Stage IIB (Importance):  The importance of each item on the draft questionnaire was rated by the 
same ten patients on a five point Likert scale (1 == no importance, 5 = very important).  An item was 
deemed to be of low importance and removed from the questionnaire if >40% of the participants rated 
it as three or less. 
Stage IIC (Correlation):  The response to each item on the draft questionnaire was rated on a five 
point Likert scale (1 = strongly disagree, 5 = strongly agree).  This was then given to 16 treatment-
naïve VCD patients.  A correlation matrix including all the questions was produced and where the 
responses to two questions showed >75% correlation the one previously rated with the lowest 
importance was removed.  The remaining statements comprised the long version VCDQ which 
underwent further validation as outlined below 
 
Stage III: Preliminary Validation 
Stage IIIA (Test-Retest reliability):  Eight of the VCD patients were retested with the VCDQ after a 
minimum of one week.  
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Stage IIIB (Concurrent Validity):  There are no other specific VCD questionnaires in use that we are 
aware of but prior to the development of the VCDQ we had devised a VCD visual analogue scale 
(VAS) for use in clinical practice as part of the initial assessment, and we used this as well as the St. 
George's Respiratory Questionnaire [18] (SGRQ, with kind permission of St. George's University of 
London Medical School) to investigate concurrent validity.  Both the VAS and SGRQ were given to 
15 participants with VCD along with the VCDQ.   
Stage III C (Performance):  The VCDQ was given to a new cohort of patients with VCD (including 
some with both VCD and asthma), asthma alone, and healthy controls, in order to compare response 
across these three groups. We then assessed the questionnaire’s responsiveness to change by 
measuring it in a new group of VCD patients before and after a course of speech and language 
therapy.  No other changes to treatment (e.g. where there was co-existent respiratory disease) were 
made during the period of speech and language therapy.  At the same time we asked patients to 
complete a Global Rating of Change Score (GRCS), a 7-point self-completed scale whereby patients 
rate how much their condition has changed over the treatment period, with negative scores (-3, -2, -1) 
associated with deterioration (very much, much or minimally worse), 0 representing no change and 
positive scores (3, 2, 1) associated with improvements (very much, much, minimally better).  We 
were thus able to estimate the minimal important difference in the VCDQ that was associated with an 
important improvement in patient symptoms.  
 
Statistical analysis 
Data analysis was performed using SPSS 15 (SPSS Inc. Chicago, USA).  Correlations between the 
individual items of the questionnaire, between the VCDQ and the VAS, SGRQ total, and the three 
individual domains of the SGRQ were assessed using Spearman's rank coefficient (expressed as 
Interclass Correlation Coefficient, ICC, which compares groups of data rather than paired data).   
The Mann-Whitney U Test was used to compare the VCD group with both the asthma group and the 
healthy controls, and Wilcoxon’s Signed Rack Test for paired pre- and post-treatment data  
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RESULTS 
Ninety participants took part in total: 47 with VCD, including 24 with coexistent lung disease (20 
with asthma, two with bronchiectasis and two with chronic obstructive pulmonary disease); and 43 
controls comprising 29 people with asthma and 14 healthy volunteers.  All of the patients with VCD 
had the laryngoscopic appearance of classical inspiratory VCD, except for four who had mixed 
inspiratory and expiratory VCD, and one with expiratory VCD only. Demographic details for each 
group are shown in Table 1.  There were significant between group differences in % predicted FEV1 
and FVC (ANOVA p < 0.05), and in gender (χ2 p < 0.05).  All of the VCD patients had been referred 
to speech and language therapy (and were at various stages in their therapy) at the time of 
participation. 
 
Stage I: Item Generation 
The focus groups produced a long list of 17 items relating to the experience of VCD amongst the 
patient-volunteers and healthcare professionals. 
 
Stage II: Item Reduction 
Stage IIA (Face Validity):  Four of the 10 participants with VCD rating each item felt that “I don’t 
have pins & needles and / or tingling during attacks” was too ambiguous and therefore this was 
removed from the long list.  The question "My symptoms cause me to avoid certain situations" was 
also removed as the healthcare professionals felt that it was too vague. 
Stage IIB (Importance): "My attacks can be triggered by stress" was removed from the VCDQ 
because of low importance leaving a 14 item draft.  
Stage IIC (Correlation): There were two clear correlations seen within the 14 item VCDQ.  “I feel 
frustrated that none of the treatments (e.g. inhaler) I’m given work” correlated with “I am frustrated 
that my symptoms have not been understood correctly” (r = 0.75; p<0.001).  The latter was rated as 
more important previously and hence the former discarded.  Secondly, “I’m aware of other specific 
triggers that cause attacks” correlated with “Moving away from the trigger and/or environment helps 
to relieve the attack” (r = 0.76; p<0.001).  In this case the former was rated as the most important and 
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so retained.  This left the final 12 item version of the VCDQ (the 12 items are listed in table 2), with a 
possible total score range of 12 to 60 
 
Stage III: Preliminary Validation 
Stage IIIA (Test-Retest reliability):  A strong correlation (ICC= 0.937, p= 0.001) was found between 
the total VCDQ scores of the eight VCD patients who were retested, indicating very strong 
repeatability. 
Stage IIIB (Concurrent Validity): The results of the concurrent validity with the SRGQ and the VAS 
are shown in table 3.  The results of the VCDQ correlated strongly with the VAS, but with neither the 
total nor domain-scores of the SGRQ. 
Stage III C (Performance): 
The VCDQ total score was significantly different in the VCD groups versus both the healthy control 
group (z= -5.390, p< 0.001) and the asthma group (z= -5.730, p< 0.001).  A histogram of total scores 
for each group is shown in figure 1.  Within the VCD group there was no difference in VCDQ score 
between those with (median score 48, range 35 – 56) and without (median score 50, range 34 – 60) 
coexistent lung disease.  
The median (interquartile range) VCDQ score pre-treatment was 50.5 (48.0 – 54.8) points and post-
treatment 35.0 (29.3 – 41.8) points [median (interquartile range) difference 15.5 (9.3 – 19.0) points, p 
< 0.001] When self-rating their response to therapy by the global rating of change score all 20 patients 
reported that their symptoms had improved: seven reported “minimally better”, 10 “much better” and 
three “very much better”.  The minimal difference in VCDQ in those reporting “minimally better” 
was 4 and “much better” was 7. 
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DISCUSSION 
We have developed the first questionnaire for VCD based on patient-reported symptoms, and 
validated it in breathless patients with the condition.  The VCDQ score was significantly higher in 
patients with VCD compared not only to healthy volunteers, but more importantly to those with 
asthma alone.  The VCDQ was also responsive to changes in treatment, and we are able to suggest a 
minimal important difference for use in future therapeutic trials.   
 
Although the prevalence is not yet known, systematic screening in patients with breathlessness does 
indicate VCD is a significant problem amongst patients presenting to the chest clinic [4, 11].  This is 
not reflected however in international guidelines; the British Thoracic Society asthma guideline for 
example mentions VCD only once [8]. Furthermore specialist diagnostic and treatment services are 
not widely available.  A recent survey performed by us amongst healthcare professionals in the North 
West of England found that 113 of 126 had either “never heard of” or knew “little” about VCD (data 
on file).  This level of knowledge was similar amongst the speech and language therapists surveyed 
with only 2 of 15 assessing that they had “good” knowledge of the condition, even though speech and 
language therapy is the cornerstone of management [16].  Understanding the sensations and 
symptoms that patients with VCD report is important to enable healthcare professionals to consider 
the diagnosis when appropriate in breathless patients.  
 
We have validated the VCDQ in line with the process undertaken for previous respiratory 
questionnaires [17].  When patients were retested after a week the VCDQ produced correlating results 
showing that it has strong test-retest reliability.  After a block of speech and language therapy, the 
score improved significantly in line with the patients’ own rating of improvement.  The VCDQ 
therefore has potential as a symptom monitoring tool, similar to the Leicester Cough Questionnaire 
[17] or SGRQ [18], and may be used to monitor response to speech and language therapy and any 
future treatment developments.  The VCDQ scores correlated with our previously developed VAS but 
not with the SRGQ total or domain scores.  This is perhaps not surprising; whilst the SRGQ was 
developed to explore symptoms in respiratory disease it has been tested only in lung disease and not 
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upper airways disease such as VCD, and so would be expected to cover a different range of symptoms 
and concerns. 
 
There are several methods for estimating the minimal important difference (MID) in a symptom-based 
questionnaire [19]. We have elected to assess a patient-reported outcome, the Global Rating of 
Change, in order to give an overview of the degree of change experienced by the patients.  Such 
methods have previously been used for the validation of other respiratory scores [17].  The MID has 
been defined as the smallest difference that patients perceive to be beneficial [20] and hence previous 
studies have judged this to equate to a “minimal” improvement in global assessment or better.  In our 
study this results in an MID of only 4, although we would also support the use of a higher cut-of 7 to 
indicate a greater improvement, corresponding with “much better” on the GRCS. 
 
This questionnaire was not designed to be a diagnostic tool for VCD.  The statements were drawn 
from patients’ symptoms and experiences, and therefore may not be specific to the condition.  
However, the VCDQ may have future potential to be refined and developed into a diagnostic 
questionnaire, as patients with VCD scored much higher than both healthy controls and asthmatics.  
At 12 items its complexity make it less than ideal for everyday clinical use, and further testing and 
refinement will be required if it is to be considered as a diagnostic aid.  The prevalence of VCD 
within the cohort was 41% (31/74), which is not a true representation of the real world prevalence or 
even that seen in within respiratory clinics (estimated at around 12% by Morris [10]).  Further testing 
will be needed to obtain a sensitivity and specificity for VCD versus asthma (and other causes of 
breathlessness) where the prevalence of VCD is lower, such as in general respiratory clinics or 
primary care, as well as to account for other respiratory conditions, in particular upper airways 
diseases such as rhinosinusitis.   
 
In summary, we have developed the first validated questionnaire for use in symptom monitoring in 
VCD.    We would suggest such a tool is essential to guide future therapeutic refinements in this much 
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neglected area.  Furthermore, understanding the symptoms that patients with VCD experience will 
also aid in early recognition, and may lead to the development of a diagnostic aid.   
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Table 1: Demographic details of the included participants 
 VCD only 
n = 23 
VCD + lung 
disease 
n = 24 
Asthma only 
n = 29 
Healthy 
n = 14 
Age mean (SD) yrs 52.4 (19.3) 48.5 (16.0) 55.3 (12.8) 49.0 (19.3) 
Gender n (%) male 2 (9) 6 (25) 13 (45) 3 (21) 
FEV1 mean (SD) % 
predicted 
99.4 (25.0)
n = 15 
79.9 (23.7)
n = 23 
60.0 (20.7)
n = 27 
78.1 (15.0) 
n = 7 
FVC mean (SD) % 
predicted 
104.4 (27.4)
n = 15 
93.9 (22.8)
n = 22 
87.6 (20.0)
n = 27 
91.7 (13.0) 
n = 7 
Asthma BTS 
treatment 
step n (%) 
1 0 (0) 0 (0)  
2 1 (5) 1 (3)
3 4 (20) 4 (14)
4 12 (60) 9 (31)
5 3 (15) 15 (52)
Blood eosinophils 
x109 cells/ml median 
(range) 
0.19 
(0.02 – 0.42) 
n = 19 
0.15 
(0.00 – 0.78) 
n = 24 
0.27 
(0.01 – 1.03) 
n = 28 
0.21  
(0.05 – 0.50) 
n = 10 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 2: The 12-item Vocal Cord Dysfunction Questionnaire (VCDQ) 
Question 
Disagree 
strongly 
Disagree Neither 
agree 
nor 
disagree 
Agree Agree 
Strongly 
Score
 1 2 3 4 5 
1.My symptoms are confined to 
my throat / upper chest 
 
2. I feel like I can’t get breath past 
a certain point in my throat / 
upper chest because of restriction  
 
3. My breathlessness is usually 
worse when breathing in 
 
4. My attacks typically come on 
very suddenly 
 
5. I feel that there is something in 
my throat that I can’t clear 
 
6. My attacks are associated with 
changes in my voice 
 
7. My breathing can be noisy 
during attacks 
 
8. I’m aware of other specific 
triggers that cause attacks 
 
9. My symptoms are associated 
with an ache or itch in my throat 
 
10. I am frustrated that my 
symptoms have not been 
understood correctly 
 
11. I am unable to tolerate any 
light pressure around the neck, 
e.g. tight clothes or bending the 
neck 
 
12. The attacks impact on my 
social life 
 
TOTAL 
 (12-60)
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Table 3: Concurrent Validity - Comparing VCDQ with the SGRQ and VAS 
 SGRQ 
 
 
 
VAS Total
Total Symptoms Activity Impacts 
Spearman's Rank 0.414 0.258 0.465 0.466 0.739
P = 0.125 0.353 0.081 0.080 0.001
 
 
Figure Legends 
Figure 1: Comparison of the 12 item VCDQ total scores between VCD and Non-VCD. 
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